Your lab results and health history Blood work plays a key role in safe and effective dosing
While Alnylams Phase III APOLLO-B study hit both key primary and secondary endpoints, the FDA stated in the documents that the effects of patisiran compared to placebo on both endpoints were small, of questionable clinical meaningfulness, and may not be detectable by patients. Major discussion points during the adcomm meeting included whether these key endpoints were appropriate to ascertain clinical meaningfulness in the ATTR-CM population, and panelists expressed varying opinions on whether the magnitude of the benefit seen in trial data was clinically meaningful
The STAT News coverage noted that if the FDA ultimately reclassifies the compounds and they are produced by compounding pharmacies, clinicians would have discretion to prescribe them outside the narrow indications under review, meaning a substance reviewed only for ulcerative colitis could legally be prescribed for any purpose a physician deemed appropriate
9 However, this class of drug is associated with a high risk of cognitive impairment and delirium
Inflammatory markers tracked the VAT response, with CRP and IL-6 falling and adiponectin rising in patients with substantial VAT loss (PMID 21516030)